Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Non-Hodgkin lymphoma Stories

2010-07-27 08:00:00

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 27 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development. The compound, SHP-141, is a first-in-class topical histone deacetylase inhibitor with the potential to treat both early- and late-stage CTCL. Through the partnership, LLS will provide funding of...

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing. Blinatumomab is the first in a...

2010-06-08 11:27:09

Molecular imaging is leading to more individualized and effective treatment for non-Hodgkin's lymphoma by providing a map to guide the path of therapy According to a study presented at SNM's 57th Annual Meeting, molecular imaging can evaluate and optimize non-Hodgkin's lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material and mimics the body's own immune response to target and kill cancer cells while sparing nearby healthy tissues. "By...

2010-06-05 17:07:00

CHICAGO and SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase I study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL) and Waldenstroms Macroglobulinemia (WM). These data are being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting...

2010-06-03 11:49:00

HACKENSACK, N.J., June 3 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used...

2010-05-21 06:45:00

BETHESDA, Md., May 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences. Blinatumomab (MT103), the Company's lead product candidate, will be the subject of two oral presentations at the 15th Annual Congress of the...

2010-05-14 09:15:13

Smoking, obesity and alcohol use are associated with poorer survival A new study led by researchers from Mayo Clinic in collaboration with six other U.S. institutions has found that patients with non-Hodgkin's lymphoma who smoked, consumed alcohol or were obese before their cancer diagnosis had poorer overall survival, compared to patients who did not have these risk factors. This association held after accounting for clinical and demographic factors, and also when considering only deaths due...

2010-05-11 13:20:13

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv©, Ph.D., of the University of Toronto....

2010-04-19 14:36:56

In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma. Non-Hodgkin Lymphoma is a cancer of the immune system and is the most common hematologic malignancy in the United States. At the 101st Annual Meeting of the American Association for Cancer Research (AACR), the researchers report that the risk of...

2010-04-09 00:15:00

SEATTLE, April 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration (the "FDA") regarding its New Drug Application ("NDA") for Pixuvri(TM) (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). The FDA cited as its primary reason for the action its concerns previously raised at the Oncologic Drugs Advisory...